Article Details

9 Meters gets $70M debt facility for phase 3 development of short bowel syndrome drug

Retrieved on: 2022-06-30 13:28:03

Tags for this article:

Click the tags to see associated articles and topics

9 Meters gets $70M debt facility for phase 3 development of short bowel syndrome drug. View article details on hiswai:

Excerpt

9 Meters Biopharma (NMTR) on Thursday said it had entered into a debt financing agreement for up to $70M to support the phase 3 development of its ...

Article found on: seekingalpha.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up